JudithKarpMD

Oncology • Baltimore, MD

Professor of Oncology and Medicine, Director Leukemia Program, Johns Hopkins

Join to view full profile

Dr. Karp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Karp's full profile

Already have an account?

Office
600 N Wolfe St
Baltimore, MD 21287
Phone+1 410-955-8964
Is this information wrong?

Education & Training

Johns Hopkins UniversityResidency, Internal Medicine, 1972 - 1974
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1971 - 1972
Stanford University School of MedicineClass of 1971

Certifications & Licensure

MD State Medical License 1975 - 2016

Clinical Trials

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia Start of enrollment: 1999 Jun 01
Completed
Phase 1
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1
MS-275 in Treating Patients With Hematologic Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 1
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers Start of enrollment: 2001 Apr 01
Completed
Phase 2
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2001 Oct 01
Completed
Phase 2
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Start of enrollment: 2002 Jun 01
Completed
Phase 2
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2004 Jan 01
Completed
Phase 1
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2005 Mar 01
Completed
Phase 1
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders Start of enrollment: 2005 Nov 01
Completed
Phase 1
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia Start of enrollment: 2007 Apr 01
Completed
Phase 1
Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly Diagnosed Acute Myelogenous Leukemia (AML) Start of enrollment: 2011 May 01
Join now to see all

Publications & Presentations

PubMed

Genomic testing and patient rights.
Jones, C., Davis, D., Karp, J.> ;Journal of the National Cancer Institute. 2024 Feb 27
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Michael J Hochman, Megan Othus, Robert P Hasserjian, Alex Ambinder, Andrew Brunner, Mary-Elizabeth M Percival, Christopher S Hourigan, Ronan Swords, Amy E DeZern, Elih...> ;Leukemia. 2023 Sep 1
1 citations
Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia.
Stephanie Franco, Xue Geng, Valeriy Korostyshevskiy, Judith E Karp, Catherine Lai> ;Cancer. 2023 Oct 1
3 citations
Ethics and Clinical Research: Improving Transparency and Informed Consent in Phase I Oncology Trials.
Paul H Frankel, Susan Groshen, Jan H Beumer, Laura Cleveland, Edward S Kim, Judith E Karp> ;Journal of Clinical Oncology. 2023 Apr 20
8 citations
The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?
Michael R Cook, Judith E Karp, Catherine Lai> ;Ejhaem. 2022 Feb 1
2 citations
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III r...
Selina M. Luger, Victoria Wang, Jacob M. Rowe, Mark R. Litzow, Elisabeth Paietta, Rhett P. Ketterling, Hillard M. Lazarus, Witold B. Rybka, Michael Craig, Judith E. Ka...> ;Leukemia Research. 2021 Oct 28
5 citations
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults w...
Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, Jackie Greer, B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Stev...> ;Leukemia Research. 2021 Sep 10
9 citations
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.
Kimberley Doucette, Mary Elizabeth Percival, Lacey Williams, Adrese Kandahari, Allison Taylor, Shuqi Wang, Jaeil Ahn, Judith E. Karp, Catherine Lai> ;Hematological Oncology. 2021 Sep 9
10 citations
Advances in therapeutic options for newly diagnosed, high-risk AML patients.
Kimberley Doucette, Judith E. Karp, Catherine Lai> ;Therapeutic Advances in Hematology. 2021 May 5
21 citations
Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
Lacey Williams, Kimberley Doucette, Judith E. Karp, Catherine Lai> ;Bone Marrow Transplantation. 2021 Mar 8
2 citations
CDK2-mediated upregulation of TNFa as a mechanism of selective cytotoxicity in acute leukemia
Husheng Ding, Nicole D. Vincelette, Cordelia D. McGehee, Mira A. Kohorst, Brian D. Koh, Annapoorna Venkatachalam, X. Wei Meng, Paula A. Schneider, Karen S. Flatten, Ke...> ;Cancer Research. 2021 May 15
32 citations
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Keith W. Pratz, Michelle A. Rudek, B. Douglas Smith, Judith E. Karp, Ivana Gojo, Amy E. DeZern, Richard J. Jones, Jackie Greer, Christopher D. Gocke, Maria R. Baer, Vu...> ;Biology of Blood and Marrow Transplantation. 2020 Feb 1
44 citations
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Elihu H. Estey, Judith E. Karp, Ashkan Emadi, Megan Othus, Robert Peter Gale> ;Leukemia. 2020 Jan 8
15 citations
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS
Joshua F. Zeidner, Hanna A. Knaus, Amer M. Zeidan, Amanda L. Blackford, Raul Montiel-Esparza, Hubert Hackl, Gabrielle T. Prince, Lukasz P. Gondek, Gabriel Ghiaur, Marg...> ;Leukemia. 2020 Jan 3
7 citations
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Renu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, Ivana Gojo, Judith E. Karp, Jacqueline Greer, Alice P. Chen, Richard Piekarz, Brian F. Kiesel, Jogarao V. S. Gob...> ;Cancer Chemotherapy and Pharmacology. 2019 Feb 1
20 citations
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Mark R. Litzow, Xin V. Wang, Martin Carroll, Judith E. Karp, Rhett P. Ketterling, Yanming Zhang, Scott H. Kaufmann, Hillard M. Lazarus, Selina M. Luger, Elisabeth Paie...> ;American Journal of Hematology. 2019 Jan 1
110 citations
Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.
Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel-Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Jud...> ;JCI Insight. 2018 Nov 2
48 citations
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Ivana Gojo, Jan H. Beumer, Keith W. Pratz, Michael A. McDevitt, Maria R. Baer, Amanda L. Blackford, B. Douglas Smith, Steven D. Gore, Hetty E. Carraway, Margaret M. Sh...> ;Clinical Cancer Research. 2017 Feb 1
32 citations
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leuk...
Keith W. Pratz, Michelle A. Rudek, Ivana Gojo, Mark R. Litzow, Michael A. McDevitt, Jiuping Ji, Larry M. Karnitz, James G. Herman, Robert J. Kinders, B. Douglas Smith,...> ;Clinical Cancer Research. 2017 Feb 15
Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018.
Binzel, K.,Adelaja, A.,Wright, C. L.,Scharre, D.,Zhang, J.,Knopp, M. V.,Teoh, E. J.,Bottomley, D.,Scarsbrook, A.,Payne, H.,Afaq, A.,Bomanji, J.,van As, N.,Chua, S.,Hos...> ;EJNMMI Res. 2018 Jan 25
17 citations
Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment.
Robert Amson, Christian Auclair, Fabrice Andre, Judith E. Karp, Adam Telerman> ;Results and Problems in Cell Differentiation. 2017 Jan 1
4 citations
Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao V. S. Gobburu, Jiuping Ji, Jacqueline Greer, Richard Piekarz, Judith E. Karp, Keith W. Pratz, Michelle A. Rudek> ;Clinical Cancer Research. 2017 Nov 1
10 citations
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J. Norsworthy, Amy E. DeZern, Hua Ling Tsai, Wesley Hand, Ravi Varadhan, Steven D. Gore, Ivana Gojo, Keith W. Pratz, Hetty E. Carraway, Margaret M. Showel, Micha...> ;Leukemia Research. 2017 Oct 1
36 citations
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
Jonathan Webster, Raoul Tibes, Lawrence E. Morris, Amanda L. Blackford, Mark R. Litzow, Mrinal M. Patnaik, Gary L. Rosner, Ivana Gojo, Robert J. Kinders, Lihua Wang, L...> ;Leukemia Research. 2017 Oct 1
154 citations
Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironm...
Jennifer Ding, Judith E. Karp, Ashkan Emadi> ;Cancer Biomarkers. 2017 Jul 4
Join now to see all

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018

Press Mentions

Improving Transparency in Phase 1 Clinical TrialsFebruary 9th, 2023
Rana R. McKay, MD: Developing Clinical Trials to Answer Questions Raised in PracticeApril 20th, 2022
Judith Esther Karp, MD, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's WhoDecember 13th, 2017